TERT promoter mutations in gliomas and a subset of tumors

Patent metadata

Field	Value
Publication number	US-11306364-B2
Application number	US-202016928164-A
Country	US
Kind code	B2
Filing date	Jul 14, 2020
Priority date	Feb 18, 2012
Publication date	Apr 19, 2022
Grant date	Apr 19, 2022

Abstract

We surveyed 1,230 tumors of 60 different types and found that tumors could be divided into types with low (<15%) and high (≥15%) frequencies of TERT promoter mutations. The nine TERT-high tumor types almost always originated in tissues with relatively low rates of self renewal, including melanomas, liposarcomas, hepatocellular carcinomas, urothelial carcinomas, squamous cell carcinomas of the tongue, medulloblastomas, and subtypes of gliomas (including 83% of primary glioblastoma, the most common brain tumor type). TERT and ATRX mutations were mutually exclusive, suggesting that these two genetic mechanisms confer equivalent selective growth advantages. In addition to their implications for understanding the relationship between telomeres and tumorigenesis, TERT mutations provide a biomarker for the early detection of urinary tract and liver tumors and aid in the classification and prognostication of brain tumors.

First claim

The invention claimed is:

1. A method of identifying a mutation in a human subject and treating a human subject, comprising:
subjecting a nucleic acid sample obtained from a tumor of the human selected from the group consisting of: glioma, astrocytoma, oligodendroglioma, and oligoastrocytoma, to a reaction whereby reaction products are formed;
detecting in the reaction products from the human tumor a somatic mutation at nucleotide chr5 1,295,250 in hg19; and
administering to the subject with the somatic mutation a therapy selected from the group consisting of chemotherapy, radiotherapy, biological therapy, or surgery.

2. The method of claim 1 , wherein the tumor is a glioma.

3. The method of claim 1 , wherein the tumor is an astrocytoma.

4. The method of claim 1 , wherein the tumor is an oligodendroglioma.

5. The method of claim 1 , wherein the tumor is an oligoastrocytoma.

6. The method of claim 1 , wherein the tumor is a primary glioblastoma.

7. The method of claim 1 , wherein the reaction comprises amplifying the promoter or part of the promoter of a telomerase reverse transcriptase (TERT) gene to form an amplicon.

8. The method of claim 7 , wherein the amplicon is sequenced.

9. The method of claim 7 , wherein the amplicon is hybridized to a mutation specific oligonucleotide.

10. The method of claim 7 , wherein the reaction employs mutation-specific amplification primers.

11. The method of claim 1 , wherein the reaction is a nucleic acid hybridization reaction.

12. The method of claim 11 , wherein the reaction employs a mutation-specific hybridization probe.

13. The method of claim 1 , wherein the reaction is a nucleic acid sequencing reaction.

14. The method of claim 1 , wherein the nucleic acid sample is obtained from a primary tumor.

15. The method of claim 1 , wherein prior to the step of subjecting, nucleic acids are extracted from a primary tumor sample.

16. The method of claim 1 , further comprising:
subjecting a nucleic acid sample obtained from a non-tumor tissue of the human to the reaction; and
confirming that the somatic mutation detected in the tumor tissue is not in the nucleic acid sample obtained from the non-tumor tissue.

17. The method of claim 1 , wherein the therapy is chemotherapy.

18. The method of claim 1 , wherein the therapy is radiotherapy.

19. The method of claim 1 , wherein the therapy is biological therapy.

20. The method of claim 1 , wherein the therapy is surgery.

21. A method of detecting a mutation in a human subject and treating a human subject, comprising:
subjecting nucleic acid samples obtained from a plurality of tumors of a plurality of humans to a reaction to form reaction products wherein the plurality of tumors are selected from the group consisting of: glioma, astrocytoma, oligodendroglioma, and oligoastrocytoma;
detecting in the reaction products of at least one of the plurality of nucleic acid samples obtained from the plurality of tumors a somatic mutation at nucleotide chr5 1,295,250 in hg19; and
administering a therapy to at least one of the human subjects in whose tumor the somatic mutation was detected, wherein the therapy is selected from the group consisting of chemotherapy, radiotherapy, biological therapy, or surgery.

22. The method of claim 21 , wherein the nucleic acid samples obtained from the plurality of tumors are obtained from primary tumors.

23. The method of claim 21 , wherein prior to the step of subjecting nucleic acid samples obtained from the plurality of tumors, nucleic acids are extracted from primary tumor samples.

24. The method of claim 21 , wherein the tumors are gliomas.

25. The method of claim 21 , wherein the tumors are primary glioblastomas.

26. The method of claim 21 , wherein the tumors are astrocytomas.

27. The method of claim 21 , wherein the tumors are oligodendrogliomas.

28. The method of claim 21 , wherein the tumors are oligoastrocytomas.

29. The method of claim 21 , wherein the reaction comprises amplifying the promoter or part of the promoter to form an amplicon.

30. The method of claim 29 , wherein the reaction employs mutation-specific amplification primers.

31. The method of claim 29 , wherein the amplicon is sequenced.

32. The method of claim 29 , wherein the amplicon is hybridized to a mutation specific oligonucleotide.

33. The method of claim 21 , wherein the reaction is a nucleic acid hybridization reaction.

34. The method of claim 21 , wherein the reaction is a nucleic acid sequencing reaction.

35. The method of claim 21 , wherein the therapy is chemotherapy.

36. The method of claim 21 , wherein the therapy is radiotherapy.

37. The method of claim 21 , wherein the therapy is biological therapy.

38. The method of claim 21 , wherein the therapy is surgery.

39. The method of claim 21 , further comprising:
subjecting a plurality of nucleic acid samples obtained from a plurality of non-tumor tissues of the plurality of humans to the reaction; and
confirming that the somatic mutation detected in the tumor tissue of the at least one human subject is not present in the nucleic acid sample obtained from the non-tumor tissue of the at least one human subject.

Assignees

• Univ Duke
• Univ Johns Hopkins

Inventors

• Yan Hai
• Vogelstein Bert
• Papadopoulos Nickolas
• Kinzler Kenneth W
• Jiao Yuchen
• Bettegowda Chetan
• Bigner Darell D
• Reitman Zachary J
• Killela Patrick J

Classifications

• C12Q1/6886 Primary

  for cancer (immunoassay for cancer G01N33/575) · CPC title

• C12Q2600/156

  Polymorphic or mutational markers · CPC title

• C12Q2600/112

  Disease subtyping, staging or classification · CPC title